Drug news and alerts

The company that makes RELYVRIO^® announced on April 4th, 2024, the decision to voluntarily withdraw the product from the market in the U.S. RELYVRIO^® will no longer be available for new patients. RELYVRIO^® was used for the treatment of amyotrophic lateral sclerosis (ALS) in adults. The company made this decision after it failed to prove to be effective in a large clinical trial.

On March 27, 2024, the U.S. Food and Drug Administration (FDA) announced that Amneal Pharmaceuticals, LLC. is voluntarily recalling four (4) lots of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, at the consumer level. The company is initiating this recall due to the potential for some bottles to have dosing above the maximum daily dose allowance, which may be harmful.

Drug recall for Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL

On September 29, 2023, the U.S. Food and Drug Administration (FDA) announced that KVK-Tech, Inc. is voluntarily recalling one (1) lot of its Betaxolol Tablets, USP 10 mg. The company is initiating this recall due to a single Oxycodone HCl  5 mg tablet found on the packaging line for Betaxolol.

Drug recall for Betaxolol Tablets, USP 10 mg

On September 22, 2023, the U.S. Food and Drug Administration (FDA) announced that VistaPharm LLC is voluntarily recalling one (1) lot of Sucralfate Oral Suspension, 1g/10mL due to Bacterial contamination in the product.

Drug recall for Sucralfate Oral Suspension, 1g/10mL

On September 11, 2023, the U.S. Food and Drug Administration (FDA) announced that Novartis is voluntarily recalling one (1) lot of its Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/ml. The company is initiating this recall due to crystal formation in some bottles, which could possibly result in incorrect dosing.

Drug recall for Sandimmune^® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL

The Harvard Drug Group, LLC is voluntarily recalling one lot (lot #T04769) of Dronabinol Capsules, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules, 20 mg. Ziprasidone is used for the treatment of schizophrenia or bipolar disorder. Dronabinol is used for anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS), and/or nausea and vomiting. The drugs are being recalled due to a potential product labelling mix-up.

Drug recall for Dronabinol Capsules and Ziprasidone Hydrochloride Capsules

The U.S. Food and Drug Administration (FDA) announced on July 28,2023 that Lupin Pharmaceuticals Inc. is voluntarily recalling two (2) lots of Tydemy (Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets 3mg/0.03mg/0.451 mg and Levomefolate Calcium Tablets 0.451 mg), because tests showed the medication has decreased levels of ascorbic acid (an inactive ingredient) that could result in reduced effectiveness which could lead to potentially unexpected pregnancy.

Drug recall for Tydemy

On July 6, 2023 Cipla Limited announced it is voluntarily recalling six batches of Albuterol Sulfate Inhalers, 90 mcg (200 Metered Inhalation). Albuterol Sulfate is indicated for the treatment of acute asthma exacerbations. The drugs are being recalled due to a potential container defect that may result in the recommended dose of albuterol not being delivered, which may result in life-threatening consequences.

Drug recall for Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation)

The U.S. Food and Drug Administration (FDA) has announced that Camber Pharmaceuticals, Inc. is voluntarily recalling one (1) lot of Atovaquone Oral Suspension, USP 750mg/5m due to potential bacterial contamination in the product.

Drug recall notice for Atovaquone Oral Suspension

The U.S. Food and Drug Administration (FDA) announced on April 6, 2023 the final decision to withdraw approval of Makena and its generic. As a result of this withdrawal of approval, Makena and its generics are now unapproved products. Approvals of the medications have been withdrawn because Makena and its generics are no longer shown to be effective, and the benefits do not outweigh the risks for the indication for which they were approved.

Drug market withdrawal for Makena (hydroxyprogesterone caproate injection)

The U.S. Food and Drug Administration (FDA) has announced on April 26, 2023 that Akorn Operating Company LLC is voluntarily recalling all its drug products as the company has shut down operations due to bankruptcy, and is unable to guarantee the quality of the products.

Drug recall for all drug products from Akorn

Ascend Laboratories LLC is voluntarily recalling one (1) lot of Dabigatran Etcxilate Capsules, USP 75 mg and 150 mg, prescribed as an oral anticoagulant to lower the risk of stroke and blood clots. This drug is being recalled due to the presence of a nitrosamine impurity being above the established Acceptable Daily Intake (ADI) level.

Drug recall notice for Dabigatran Etcxilate Capsules, USP 75 mg and 150 mg 

IBSA Pharma, Inc. is voluntarily recalling 27 lots of TIROSINT^®-SOL (levothyroxine sodium) Oral Solution, which is indicated to treat hypothyroidism and pituitary thyrotropin suppression. This drug is being recalled due to tests showing slight decrease below 95.0% of its labeled amount in levothyroxine sodium (T4) for some lots.

Drug recall notice for Tirosint-Sol (levothyroxine sodium)

Apotex Corp. is voluntarily recalling six (6) lots of Brimonidine Tartrate Ophthalmic Solution, 0.15%, which is indicated for the reduction of elevated intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension. This drug is being recalled due to potential cracks in the bottle caps, which may impact sterility and cause side effects.

Drug recall notice for Brimonidine Tartrate Ophthalmic Solution, 0.15%

Mylan Pharmaceuticals Inc. is voluntarily recalling one (1) lot of Octreotide Acetate Injection, 500 mcg/mL, which are packaged in a carton of ten 1mL syringes. It is used to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients. The injection is also indicated for certain symptomatic treatment of patients with metastatic carcinoid tumors. This drug is being recalled due to a product complaint of the presence of glass particles in a syringe.

Drug recall notice for Octreotide

Mylan Pharmaceuticals Inc. is voluntarily recalling two (2) lots of quinapril and hydrochlorothiazide tablets USP 20mg/ 12.5mg, prescribed for the treatment of hypertension i.e. to lower blood pressure. This drug is being recalled due to the presence of a nitrosamine impurity, a substance that could cause cancer in amounts above acceptable levels.

Drug recall notice for Quinapril and Hydrochlorothiazide

Mylan Pharmaceuticals Inc. is recalling a single batch (Lot # BF21002895) of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are packaged in cartons of five pens. This drug is being recalled due to the potential for the label to be missing on some pens.

Drug recall notice for Insulin Glargine Injection

The U.S. Food and Drug Administration (FDA) announced that TG Therapeutics has withdrawn Ukoniq tablets from the market due to safety concerns. This decision was made because there was an increased risk of death seen in clinical trials with this drug, and so the FDA determined the risks of treatment with Ukoniq outweigh its benefits. This means that Ukoniq is no longer available effective June 1, 2022.

Drug recall notice for Ukoniq Tablets

Teva Pharmaceuticals is recalling a single lot of Anagrelide Capsules, USP 0.5 mg (Lot Number GD01090). This drug is being recalled due to dissolution test failure detected during routine stability testing, which could result in it taking longer for the drug to dissolve once taken, and may result in the drug being less effective or ineffective.

Drug recall notice for Anagrelide 0.5 MG Capsules

Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets, 10 mg, 20 mg, 40 mg due to the presence of a nitrosamine, Nnitroso-quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level.

Drug recall notice for Accupril (Quinapril HCl) tablets

Mylan Pharmaceuticals Inc. voluntarily recalled one (1) lot of its Insulin Glargine Injection, 100 units/ml (U-100) due to the potential for the label to be missing on some vials, which may lead to administration of the wrong strength or wrong product.

Drug recall notice for Insulin Glargine Injection

Princeton, NJ, Sandoz Inc. voluntarily recalled 13 lots of oral Orphenadrine Citrate 100 mg Extended Release (ER) tablets due to the presence of a nitrosamine impurity, which may cause cancer in amounts above acceptable levels that was detected in the lots during testing.

Drug recall notice for Orphenadrine Citrate 100 mg (ER) tablets

Pfizer is voluntarily recalling six (6) lots of Accuretic tablets, as well as two authorized generics distributed by Greenstone, one(1) lot of quinapril and hydrochlorothiazide tablets, and four (4) lots of quinapril HCl/hydrochlorothiazide tablets. These drugs are being recalled due to the presence of nitrosamine, N-nitroso-quinapril, a substance that may cause cancer if detected in amounts above acceptable levels, depending on the amount of exposure.

Drug recall notice for Accuretic (Quinapril) tablets

Adamis Pharmaceuticals Corporation voluntarily recalled certain lots of Symjepi (epinephrine) Injection 0.15mg (0.15mg/0.3mL) and 0.3mg (0.3mg/0.3mL) Pre-Filled Single-Dose Syringes. This drug has certain batches being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine.

Drug recall notice for Symjepi

Mylan Pharmaceuticals Inc. is voluntarily recalling one lot (lot #BF20003118; exp. 08/2022) of Semglee^® (insulin glargine injection), 100 units/ml (U-100), 3mL prefilled pens due to possible missing labels on some pre-filled pens.

Drug recall notice for Semglee (insulin glargine injection) 3mL prefilled pens

Viona Pharmaceuticals Inc. is voluntarily recalling 23 lots of Metformin Hydrochloride Extended–Release tablets, USP 750 mg, due to the detection of Nnitrosodimethylamine, a substance that could cause cancer, during testing in one lot of the product.

Drug recall notice for Metformin hydrochloride extended-release tablets

Taro Pharmaceuticals U.S.A., Inc. is voluntarily recalling one lot (lot # AC13786, Exp 12/2022) of Clobetasol Propionate 0.05% Ointment 60 GM because routine testing found the presence of a bacteria called R. pickettii.

Drug recall notice for Clobetasol Propionate 0.05% ointment

Padagis US Pharmaceuticals Ltd. is voluntarily recalling three lots of Nitroglycerin Lingual Spray, 12g due to the remote risk that the product may not properly dispense medication.

Drug recall notice for Nitroglycerin Lingual Spray

Sandoz, Inc. is voluntarily recalling one lot (lot # SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes. This drug is being recalled due to exposure to higher temperatures than recommended during shipment, which may have significantly impacted the recalled product’s effectiveness.

Drug recall notice for Enoxaparin Sodium Injection

CSL Behring Biotherapies for Life is voluntarily recalling four lots (P10034060, P100343632, P100369102, P100369103) of Hizentra 20% (10g/50mL) due to increased reports of local hypersensitivity and other injection-site reactions after taking it.

Drug recall notice for Hizentra 20% (10g/50mL)

Lupin Pharmaceuticals, Inc. is voluntarily recalling all batches of Irbesartan (75mg, 150mg and 300mg) Tablets USP and Irbesartan and Hydrochlorothiazide (150mg/12.5mg and 300mg/12.5mg) Tablets USP due to certain test batches containing above acceptable limits of an impurity.

Drug recall notice for Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets

Eli Lilly and Company is voluntarily recalling one (1) lot (lot #D239382D; expires April 2022) of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe due to the vial of the Glucagon diluent being a liquid instead of a powder.

Drug recall notice for Glucagon Emergency Kits

Coppertone, owned by Beiersdorf, is voluntarily recalling specific lots of five Coppertone aerosol sunscreen spray products: Pure & Simple Baby SPF 50 spray, Pure & Simple Kids SPF 50 spray, Pure & Simple SPF 50 spray, Sport Mineral SPF 50 spray, and Travel-Size Sport Spray SPF 50. Coppertone decided to recall these drugs due to the presence of Benzene in these products.

Drug recall notice for Coppertone sprays

Bayer U.S. LLC is voluntarily recalling all lots of Lotrimin^® AF and Tinactin^® spray products, which are anti-fungal medications used to treat athlete’s food, jock itch, ringworm and other fungal skin infections. Bayer decided to recall these drugs due to the presence of Benzene in some samples of the products.

Drug recall notice for Lotrimin AF and Tinactin spray products

Jacobus Pharmaceutical Company Inc. is voluntarily recalling three (3) lots of f Ruzurgi (amifampridine) 10 mg tablets due to contamination.

Drug recall notice for Ruzurgi 10 mg tablets

Azurity Pharmaceuticals, Inc. is voluntarily recalling one lot of Firvanq^® (Vancomycin Hydrochloride for oral solution), Vancomycin 50 mg/mL Kits, which treats diarrhea and  Enterocolitis. The drug is being recalled due to the kit containing a different diluent bottle than Firvanq, which may cause you to take the wrong dosage.”

Drug recall notice for Firvanq^® Vancomycin 50 mg/mL Kits

Teligent Pharma, Inc. is recalling five lots of Lidocaine HCl Topical Solution 4%, 50 mL, a topical anesthetic. Teligent Pharma discovered that the affected lot was super potent, which may lead to higher doses than recommended.

Drug recall notice for Lidocaine HCI Topical Solution 4%

Atovaquone Oral Suspension is prescribed to treat pneumocystis jiroveci (pneumocystis carinii) pneumonia. KVK Tech, In., a company that makes Atovaquone Oral Suspension, USP 750mg/5ml, is voluntarily recalling 2 lots of this drug. 

Drug recall notice for Atovaquone Oral Suspension

April 30, 2021

The U.S. Food and Drug Administration (FDA) announced that Acella Pharmaceuticals, LLC is voluntarily recalling thirty-eight (38) lots of NP Thyroid^®, Thyroid Tablets, USP. The products are being recalled because testing has found these lots to be sub potent, meaning they don’t provide the amount of relief per dose as expected. If you take NP Thyroid tablets, speak with your health care professional as soon as possible to see if there are other available medicines for you. 

Drug recall notice for NP Thyroid tablets

April 20, 2021

Apotex Corp is voluntarily recalling one (3) lots of Guanfacine ER Tablets, 2 mg to the consumer level due to trace amounts of Quetiapine Fumarate.

Drug recall notice for Guanfacine tablets

 

April 6, 2021

Alembic Pharmaceuticals Inc is voluntarily recalling one (1) lot of Telmisartan Tablets, 20 mg to the consumer level due to a label mix-up.

Drug recall notice for Telmisartan tablets